In yesterday’s (29.09.2016) main broadcast of TVP 1’s “Wiadomości”Marek Filipek, MD, PhD and Stefan W. Czarniecki, MD discussed the SelectMDx Liquid Biopsy test – a urine based diagnostic test for prostate cancer.
When an elevated PSA test result is obtained, usually a prostate biopsy is subsequently performed. Unfortunately, prostate biopsy is an invasive procedure and thus complications may arise, these may include: hematospermia, hematuria, urinary retention, severe stress and in extreme cases even sepsis. On average 14 thousand prostate biopsies are performed in Poland annually, but only 30% of the procedures confirm the presence of prostate cancer. It is possible that up to 70% of prostate biopsies could be prevented.
HIFU CLINIC Prostate Cancer Center is the first clinic in Poland to offer the innovative SelectMDx Liquid Biopsy for its Patients. This test is a urine based assay, which determines the risk of detecting prostate cancer during a prostate biopsy procedure and estimates the likelihood of the cancer being aggressive. It is a non-invasive and safe procedure for the Patient. Urine liquid biopsy is a genetic test, designed for men that are being considered for primary or secondary prostate biopsy, but it can also be used as a screening tool for males of all ages at any stage in their lives.